DB16724ApprovedWithdrawnVaccines
Influenza A virus A/Tasmania/503/2020 (H3N2) recombinant hemagglutinin antigen: Overview.
- First approval
- United States, 2021
Resolves to
Compound
What you can answer from here — as of April 02, 2025
Which companies are running trials of Influenza A virus A/Tasmania/503/2020 (H3N2) recombinant hemagglutinin antigen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account